Tianjin Tianyao Pharmaceuticals Co.,Ltd. announced on the evening of November 7th that two of its subsidiaries, Hubei Jin Yao Pharmaceutical and Tianjin Jin Yao Pharmaceutical Co., Ltd, participated in the bidding for the ninth batch of national centralized drug procurement organized by the Joint Procurement Office, the glycerol fructose sodium chloride injection, dexamethasone sodium phosphate injection, citicoline sodium injection and piracetam injection of Hubei Jin Yao; and the magnesium sulfate injection and dexamethasone sodium phosphate injection, the products of Tianjin Jin Yao Pharmaceutical Co., Ltd, are planned to be selected for this centralized procurement. Among the above products, dexamethasone sodium phosphate injection is a product jointly declared.

Glycerol fructose sodium chloride injection is mainly used for treatment of cerebrovascular disease, brain injury, brain tumor, intracranial inflammation and other causes of acute and chronic intracranial hypertension, brain edema and other diseases; Dexamethasone sodium phosphate injection is mainly used for treating allergic and autoimmune inflammatory diseases; Citicoline sodium injection is mainly used for acute craniocerebral trauma and consciousness disorder after brain surgery; And piracetam injection is mainly used for memory and thinking impairment caused by brain trauma and cerebrovascular diseases; Magnesium sulfate injection is an anticonvulsant, which is mainly used for pregnancy-induced hypertension, lowering blood pressure and treating pre-eclampsia and eclampsia.

The above five preparation products all have hundreds of millions of market space in China and broad prospects. If the above products are selected, after the purchase contract is signed and implemented, the domestic sales market of the above products will be opened rapidly, the market share will be increased, the brand influence of the company will be improved, the company's preparation business will be further expanded, producing a positive impact on the company's business performance in the future.